US Dollar vs Yen

登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

ホーム
投資
株式
イギリス
LSE
Celon Pharma SA (0RKX) 銘柄情報

Celon Pharma SA (0RKX)

29.00

0.00

( 0.00% )

更新日時： 09:00:00

Celon Pharma SA (0RKX) 銘柄情報

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

プレミアム

通貨

29.00

( - )

買値

29.00

売値

29.00

出来高

0.00

0.00 日の範囲 0.00

29.00 52 週間の範囲 29.00

時価総額

前日終値

29.00

始値

-

時刻

最終取引時間

-

財務取引量

-

VWAP

-

平均取引量 (3 か月)

PLN 8,763

発行済株式数

53,856,500

配当利回り

PER

-8.4

1 株当たり利益 (EPS)

-2.36

歳入

225.6M

純利益

-122.39M

Celon Pharma S.A., an integrated pharmaceutical company, engages in the research, manufacture, and marketing of specialised generic products. The company provides drugs to treat cancers, neurological diseases, diabetes, and other metabolic disorders. Celon Pharma S.A. was founded in 2002 and is base... Celon Pharma S.A., an integrated pharmaceutical company, engages in the research, manufacture, and marketing of specialised generic products. The company provides drugs to treat cancers, neurological diseases, diabetes, and other metabolic disorders. Celon Pharma S.A. was founded in 2002 and is based in Lomianki, Poland. The company operates as a subsidiary of Glatton Sp. z o.o. 詳細を表示

セクター

-

業界

-

ウェブサイト

www.celonpharma.com

本社

Lomianki, Poland

設立

2026

Celon Pharma SA is listed in the sector of the ロンドン証券取引所 with ticker 0RKX. The last closing price for Celon Pharma was PLN29. Over the last year, Celon Pharma shares have traded in a share price range of PLN 29.00 to PLN 29.00.

Celon Pharma currently has 53,856,500 shares in issue. The market capitalisation of Celon Pharma is PLN1.56 billion. Celon Pharma has a price to earnings ratio (PE ratio) of -8.40.

表示するニュースはありません。

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	29	29	29	0	0	DE
52	0	0	29	29	29	0	0	DE
156	0	0	29	29	29	2050	29	DE
260	0	0	29	29	29	1178	29	DE

0RKX - Frequently Asked Questions (FAQ)

What is the current Celon Pharma SA share price?

The current share price of Celon Pharma SA is PLN 29.00

How many Celon Pharma SA shares are in issue?

Celon Pharma SA has 53,856,500 shares in issue

What is the market cap of Celon Pharma SA?

The market capitalisation of Celon Pharma SA is PLN 1.56B

What is the 1 year trading range for Celon Pharma SA share price?

Celon Pharma SA has traded in the range of PLN 29.00 to PLN 29.00 during the past year

What is the PE ratio of Celon Pharma SA?

The price to earnings ratio of Celon Pharma SA is -8.4

What is the cash to sales ratio of Celon Pharma SA?

The cash to sales ratio of Celon Pharma SA is 4.73

What is the registered address of Celon Pharma SA?

The registered address for Celon Pharma SA is Ogrodowa 2A, Lomianki, 05-092

What is the Celon Pharma SA website address?

The website address for Celon Pharma SA is www.celonpharma.com

CatfishHunter

CatfishHunter 1分前

https://www.globenewswire.com/news-release/2026/07/06/3322418/0/en/vivos-inc-otcqb-rdgl-receives-u-s-fda-approval-for-investigational-device-exemption-ide-to-initiate-human-clinical-feasibility-study-for-radiogel-precision-radionuclide-therapy.html

underpar71

underpar71 1分前

I would think this is a good time for another toxic 30% loan announcement, and pump the Bosch presentation.

ihubstockmover

ihubstockmover 2分前

$AMCOF - Americore Resources Identifies New Targets at Trinity Silver Project
https://www.stocktitan.net/news/AMCOF/americore-resources-identifies-new-targets-at-trinity-silver-ouh6dt9kt02u.html

Termite7

Termite7 2分前

HUGE bounce pending?!?!?! We'll see!!!!

getmoreshares

getmoreshares 2分前

NEWS July 06 2026 - 8:45AM
InvestorsHub NewsWire
Alert
Print
Share On Facebook
America's Energy Vulnerability Is Real — Compact Fusion May Be the Answer

NetworkNewsWire Editorial Coverage: The United States military is the largest single institution

trefontane

trefontane 4分前

Decent PR for $ECPL. First acquisition is operating under ECPL and profitable. This should continue to grow to a low multimillion dollar operation. They are looking to acquire more companies. The train has left the station , lets see if it can build something decent.

https://www.otc

Trooperstocks

Trooperstocks 4分前

$TDTH News: Trident Digital Tech Holdings (Nasdaq: TDTH) Founder & CEO to Convert US$8 Million of Debt into Restricted Class B Equity, Strengthening the Company’s Balance Sheet Ahead of Direct Nasdaq Ordinary-Share Trading

Trident Digital Tech Holdings Ltd
Mon, July 6, 2026 at

chemist72

chemist72 4分前

I hope all the negative nellies know how to eat crow!! lol

Go VIVOS!!

Runners123

Runners123 4分前

JRoon71

JRoon71 4分前

This is frustrating. But maybe Recordati can have some influence on placement of IPE in the recommendations in Italy.

bayougirl

bayougirl 4分前

LET'S GO!!!!♥️

BahamaPete

BahamaPete 5分前

$VMST https://investorshub.advfn.com/boards/read_msg.aspx?message_id=177760826

Zadie420

Zadie420 5分前

You said: "DCVax-l against the newer definition of GBM".
Are you referring to taking IHD out of the GBM? Tia

Ready78

Ready78 6分前

not being a lazy poster....just thought perhaps Bill C was a securities attorney guess not.....

JRoon71

JRoon71 6分前

I agree, Tseven. Ousting Sarissa would create the worst possible outcome for the stock, at this point. While Sarissa has certainly cause a lot of frustration, we need them to see this through to the best possible outcome.

Because if Sarissa sold, then more likely than not, most of the

Termite7

Termite7 7分前

HUGE upside? 100-bagger??? .......Thanks!!!

Stevenvegas

Stevenvegas 7分前

Saylor sold a ton. Caution

jimmybob

jimmybob 7分前

Morning Watch List: https://www.optionmillionaires.com/july-6th-2026-watch-list/

resx18

Good Morning $AABB

Stevenvegas

Stevenvegas 7分前

and. we're back, Careful of falling knives. Watching SOXS for entry. The mother of corrections is near imo. META gave the game away

chemist72

chemist72 8分前

BREAKING NEWS!!!
Vivos Inc. (OTCQB: RDGL) Receives U.S. FDA Approval for Investigational Device Exemption (IDE) to Initiate Human Clinical Feasibility Study for RadioGel® Precision Radionuclide Therapy From my Fidelity news feed.

getmoreshares

getmoreshares 8分前

https://pbs.twimg.com/media/HMgCrOaWsAAyBl_?format=jpg&name=small

US Market News

US Market News 8分前

Anixa Biosciences and Moffitt Cancer Center Advance Ovarian Cancer CAR-T Clinical Trial to Highest Dose Level to DateJuly 6, 2026 8:30 AM
PR Newswire (US) Multiple Patients Surviving More Than One Year, Including one Beyond Two Years, wit

US Market News

US Market News 9分前

LEIFRAS Co., Ltd. Enters Comprehensive Cooperation Agreement with Private Tutoring Provider Ando JukuJuly 6, 2026 8:30 AM
PR Newswire (US) Combining Intellectual and Physical Approaches to Improve Youth Education and Expand Leifras' Regional Education E

flipper44

flipper44 9分前

I still believe further control data will/has become available from the SurvaxM 2b trial for purposes of demonstrating even increased impact from DCVax-l against the newer definition of GBM.

Not that it is necessary for approval imho, but for purposes of valuation.

Barclays Bank Plc Autoca...

Prospect Prediction Mark...

Almonty Industries

Marine Bancorp Fla (ID)

Viaplay Group AB (PK)

Unipol Assicurazioni

AMAG Austria Metall

Italian Thai Development... (EM)

El Arts Inc Dl 01

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

ADVFN

すでにアカウントをお持ちですか？サインイン

アカウントをお持ちでないですか？登録

登録することで、ADVFN の利用規約を読み、理解し、同意したこと、および私が個人投資家であることを確認します。